AKT1 and glioma: VEGFR2 inhibition by SU1498 or Cediranib in glioma cells, including U87, suppressed different intracellular signaling cascades, such as the focal adhesion kinase (FAK), the mitogen-activated protein kinase ERK1/2, or the phosphatidylinositol 3 kinase (PI3K)/AKT pathways [16], [25], [39].